羟氯喹作为 COVID-19 的预防或治疗药物：证据说了什么？
Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
机构信息
Assistant Professor, Department of Epidemiology and Public Health, Central University of Tamil Nadu, Tiruvarur, Tamil Nadu, India.
Vice-Chancellor; Central University of Tamil Nadu, Tiruvarur, Tamil Nadu, India.
出版信息
Indian J Public Health. 2020 Jun;64(Supplement):S125-S127. doi: 10.4103/ijph.IJPH_496_20.
Hydroxychloroquine (HCQ), an antimalarial has been proposed as possible treatment for coronavirus disease-2019 (COVID-19). India has approved the use of HCQ for prophylaxis of asymptomatic health workers treating suspected or confirmed COVID-19 cases, and asymptomatic household contacts of confirmed patients. The U.S. Food and Drug Administration has issued Emergency Use Authorization for the use of HCQ to treat COVID-19 in adolescents and adults. In this review, we go over the available evidence for and against HCQ's use as prophylaxis or treatment for COVID-19, especially in the Indian context.
羟氯喹（HCQ）是一种抗疟药物，已被提议用于治疗 2019 年冠状病毒病（COVID-19）。印度已批准将 HCQ 用于治疗疑似或确诊 COVID-19 病例的无症状卫生工作者以及确诊患者的无症状家庭接触者的预防。美国食品和药物管理局已发布 HCQ 的紧急使用授权，用于治疗青少年和成年人的 COVID-19。在这篇综述中，我们回顾了 HCQ 作为 COVID-19 的预防或治疗药物的证据，特别是在印度的情况下。
Zotero 插件